I am a
Home I AM A Search Login

Papers of the Week

Papers: 19 Feb 2022 - 25 Feb 2022

2022 Feb 21

J Headache Pain



Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.


Buse DC, Winner PK, Charleston L, Hirman J, Cady R, Brevig T
J Headache Pain. 2022 Feb 21; 23(1):29.
PMID: 35189811.


A clinical ability to describe the response trajectory of patients receiving preventive migraine treatment could expedite and improve therapeutic management decisions. This post hoc analysis of the PROMISE-2 study evaluated the consistency and predictive power of Month 1 treatment response on later response in patients with chronic migraine.